€1.42
0.32% day before yesterday
L&S, Jun 28, 10:54 pm CET
ISIN
US67577R1023
Symbol
OCUP
Sector
Industry

Ocuphire Pharma Inc Share price

$1.53
-0.14 8.38% 1M
-1.57 50.65% 6M
-1.48 49.17% YTD
-2.29 59.95% 1Y
-3.32 68.45% 3Y
-19.11 92.59% 5Y
-416.07 99.63% 10Y
Nasdaq, Closing price Fri, Jun 28 2024
ISIN
US67577R1023
Symbol
OCUP
Sector
Industry

Key figures

Market capitalization $39.66m
Enterprise Value $-7.51m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.36
EV/Sales (TTM) EV/Sales -0.40
P/S ratio (TTM) P/S ratio 2.09
P/B ratio (TTM) P/B ratio 0.83
Sales growth (TTM) Sales growth -54.30%
Turnover (TTM) Turnover $19.01m
EBIT (operating result TTM) EBIT $-12.14m
Free cash flow (TTM) Free cash flow $-3.18m
Cash position $47.17m
EPS (TTM) EPS $-0.49
P/E ratio expected negative
P/S ratio expected 2.43
EV/Sales expected negative
Short interest 4.92%
Show more

Is Ocuphire Pharma Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Ocuphire Pharma Inc Share analysis

Unlock scores for free

Analyst opinions

3 Analysts have issued a Ocuphire Pharma Inc forecast:

3x Buy
100%

Analyst opinions

3 Analysts have issued a Ocuphire Pharma Inc forecast:

Buy
100%

Financial data from Ocuphire Pharma Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
19 19
54% 54%
100%
- Direct costs 0.01 0.01
-
0%
19 19
54% 54%
100%
- Selling and administrative expenses 14 14
83% 83%
75%
- Research and development costs 17 17
11% 11%
88%
-12 -12
165% 165%
-64%
- Depreciation and amortization 0.01 0.01
-
0%
EBIT (operating result) EBIT -12 -12
165% 165%
-64%
Net profit -11 -11
160% 160%
-59%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Ocuphire Pharma Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Ocuphire Pharma Inc Share News

Neutral
GlobeNewsWire
24 days ago
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy (DR) will be featured...
Neutral
GlobeNewsWire
about 2 months ago
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
about 2 months ago
FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial evaluating APX3330 in diabetic retinopathy (DR) on a validated binocular person-level scale...
More Ocuphire Pharma Inc News

Company profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Head office United States
CEO George Magrath
Employees 14
Founded 2018
Website www.ocuphire.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now